National Cancer Center of Singapore shared a post on LinkedIn about a recent article by Rebecca Dent et al, published in Annals of Oncology, adding:
“An effective new treatment for triple-negative breast cancer has emerged!
Congrats to Prof Rebecca Dent, Deputy CEO (Clinical), NCCS, and lead author of a recently published Annals of Oncology study demonstrating positive findings from a Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) to treat aggressive and previously untreated triple-negative breast cancer (TNBC).
Why are new TNBC treatments needed?
TNBC patients with previously untreated and advanced disease have poor prognosis and limited treatment options, especially when they are not candidates for immunotherapy.
The TROPION-Breast02 trial, an open-label phase III trial, tested whether the antibody drug conjugate (ADC Dato-Dd improves survival for this group of patients.
In a study of 644 patients randomised to receive either the ADC or chemotherapy, Dato-Dd demonstrated significantly improved progression-free survival (10.8 vs 5.6 months) and overall survival (23.7 vs 18.7 months).
What this means for patients:
TNBC is an aggressive and devastating disease that hits women in the prime of their lives and new treatments give hope to patients and their families.
The results of this clinical trial indicate a potential new breakthrough that improves treatment for TNBC.”
Title: Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
Authors: R. Dent, Z. Shao, P. Schmid, J. Cortes, D.W. Cescon, S. Saji, K.H. Jung, T. Bachelot, S. Wang, E.M. Ramírez, G. Basaran, A. Stradella, R. Mathiba, S.-C. Chen, K. Shen, Á. Wéber, N. Battelli, N. Niikura, T. Luo, Y.S. Chae, N. Fischbach, G. Garbaos, A. Patera, K. Zhao, P. Vuković, M.J. Maxwell, T. Traina
Read the Full Article on Annals of Oncology.
Stay updated on all scientific advances with OncoDaily.
